Dear Editor,

We recently read with interest the editorial by Gattinoni et al. \[[@CR1]\], conceptualizing 'type L' and 'type H' (typical acute respiratory distress syndrome, ARDS) phenotypes for COVID-19. We hypothesize that what the authors label a type L phenotype is actually a typical Stage 2/Stage 3 of COVID-19 pneumonia \[[@CR2]\]. Like any other pneumonia, COVID-19 pneumonia can result in complications like severe ARDS; we believe that referring to this as a 'type H phenotype' may lead to confusion. Furthermore, we are hesitant to accept the authors' hypothesis concerning the mechanism of hypoxia in the so-called type L phenotype. Here is our reasoning.

**Onset of hypoxia**

Gattinoni et al. proposed pulmonary vasoplegia as a key mechanism for the onset of severe hypoxia, but failed to give any plausible mechanism for this vasoplegia. We instead propose a 'epithelial--endothelial crosstalk' hypothesis that may provide a better explanation for the different stages of COVID-19 pneumonia:i.*Downregulation of ACE-2 on type II alveolar epithelial cells*SARS-CoV-2 enters the type II alveolar epithelial cells following binding of its spike protein to the ACE-2 receptor. This causes ACE-2 downregulation on the alveolar epithelium. Of note, SARS-CoV-2 seems to produce little or no direct cytopathic changes in the pulmonary epithelium \[[@CR3]\].ii.*Endothelial dysfunction*The downregulation of ACE-2 on pulmonary epithelium results in unopposed effects of ACE-1 on the pulmonary capillary endothelial cells. Consequently, the level of protective ACE2-Ang 1--7-mas-R activity is reduced, while the level of harmful ACE 1-Ang II-AT1-R activity is increased. Possibly, the earliest deleterious effect of ACE 1-Ang II-AT1-R overactivity is the release of a potent vasoconstrictor, endothelin-1, from the pulmonary endothelium. ACE2-Ang 1--7-mas-R mediated constitutive endothelial nitric oxide (NO) synthase activation, and NO release is inhibited \[[@CR4]\]. The intense pulmonary vasoconstriction so developed is severe, but uneven and results in the recruitment of capillary beds with relatively less vasoconstriction. As a result, the shunt fraction is increased and severe hypoxia ensues. As the disruption of the alveolar--capillary barrier progresses, proteins, fibrin, cells and fluid leak into the alveolar space, resulting in bilateral patchy ground glass opacities on CT scan.

**The evolution of the pulmonary manifestations of COVID-19 disease**

While patient-self-inflicted lung injury (P-SILI) is common, as a sole underlying mechanism for the progression of COVID-19 pneumonia to severe ARDS, it appears to be unlikely, especially, when early invasive mechanical ventilation policies are now largely adopted.

We hypothesize that 'endothelial--epithelial' interaction plays a major role in the disease progression: Following alveolar--capillary membrane disruption, SARS-CoV-2 enters the pulmonary capillaries and directly infects the pulmonary endothelial cells via ACE-2 protein on the luminal surfaces. As a result, endothelial cells assume a 'proinflammatory'/'procoagulant' phenotype. This accelerates Fas-induced apoptosis of alveolar epithelial and endothelial cells and orchestrates the cytokine storm and the progression of COVID-19 to ARDS \[[@CR5]\].

**Implications for respiratory treatment**

The above hypothesis has treatment implications that warrant further investigation. It appears that high PEEP therapy, while preventing P-SILI, can increase shunt fraction; early intubation may not prevent a transition to ARDS, and early inhaled NO, steroids and anticoagulation therapy may be potentially helpful.
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